Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Moderna (MRNA) is anticipated to report a smaller quarterly loss of $2.99 per share for the quarter ended June 2025, reflecting a 10.2% year-over-year improvement in earnings, despite an expected 47.2% decline in revenues to $127.17 million. The company is poised to likely beat consensus EPS estimates, supported by a positive Zacks Earnings ESP of +7.22% and a Zacks Rank #3, a combination historically predictive of earnings surprises. This outlook is further reinforced by Moderna's track record of beating EPS estimates in the past four consecutive quarters, though investors are advised to consider additional factors influencing stock performance ahead of the August 1 report.

Analysis

Moderna (MRNA) presents a mixed but statistically favorable outlook ahead of its June 2025 earnings report. The consensus expectation is for a significant 47.2% year-over-year revenue contraction to $127.17 million, reflecting ongoing post-pandemic normalization. However, the company is projected to report a narrower loss of $2.99 per share, a 10.2% improvement from the prior year, indicating potential progress in cost management. The key forward-looking indicator is the proprietary Zacks Earnings ESP, which stands at a positive 7.22%. This metric, combined with a Zacks Rank of #3 (Hold), historically signals a high probability (nearly 70%) of the company beating its consensus EPS estimate. This bullish signal is further supported by Moderna's strong track record, having surpassed EPS estimates in each of the last four quarters, including a 13.70% surprise in the most recent period. Despite this, the consensus EPS estimate has been revised 1.37% lower over the past 30 days, suggesting some underlying caution among analysts. The primary determinant for sustained stock performance will not be the earnings beat itself, but management's forward guidance on the August 1 call, which will provide crucial context on future revenue drivers and profitability.

Key Decisions for Investors

• Investors should consider the strong statistical likelihood of an EPS beat, driven by a +7.22% Earnings ESP and four previous consecutive surprises, as a potential catalyst for positive near-term price action.
• It is critical to look beyond the expected EPS beat and closely scrutinize the severe 47.2% year-over-year revenue decline, as this reflects the core challenge to the company's fundamental health post-pandemic.
• The most pivotal data point will be management's forward guidance during the earnings call; any commentary on cost controls, pipeline developments, or future revenue streams will likely outweigh the backward-looking earnings result in driving the stock's medium-term trajectory.